Free Trial

Haemonetics (HAE) Earnings Date, Estimates & Call Transcripts

Haemonetics logo
$89.22 -1.53 (-1.69%)
(As of 11/15/2024 ET)

Haemonetics Latest Earnings Summary

Upcoming Q3
Earnings Date
Feb. 13Estimated
Actual EPS
(Nov. 7)
$1.12 Beat By $0.03
Consensus EPS
(Nov. 7)
$1.09

Haemonetics posted Q2 2025 earnings on November 7, 2024, reporting an EPS of $1.12, which beat the consensus estimate of $1.09 by $0.03. Quarterly revenue rose 8.6% year-over-year to $345.50 million, above analysts' expectations of $342.57 million. With a trailing EPS of $2.41 and a P/E Ratio of 37.02, Haemonetics' earnings are expected to grow 15.03% next year, from $4.59 to $5.28 per share.

HAE Upcoming Earnings

Haemonetics' next earnings date is estimated for Thursday, February 13, 2025, based off prior year's reporting schedules.

Get Haemonetics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Haemonetics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

HAE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HAE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Haemonetics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242$0.65$0.74$0.70 
Q2 20242$0.91$0.93$0.92 
Q3 20242$0.95$0.96$0.96 
Q4 20242$0.87$0.88$0.88 
FY 20248$3.38$3.51$3.45 
Q1 20252$1.02$1.03$1.03 
Q2 20252$1.09$1.10$1.10 
Q3 20252$1.14$1.22$1.18 
Q4 20252$1.22$1.27$1.25 
FY 20258$4.47$4.62$4.55 
Q1 20262$1.16$1.19$1.18 
Q2 20262$1.24$1.29$1.27 
Q3 20262$1.28$1.35$1.32 
Q4 20262$1.40$1.41$1.41 
FY 20268$5.08$5.24$5.16 
Q1 20271$1.64$1.64$1.64 

Haemonetics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/13/2025
(Estimated)
------- 
11/7/2024Q2 2025$1.09$1.12+$0.03$1.58$342.57M$345.50M      
8/8/2024Q1 2025$1.03$1.02 -$0.01$1.30$335.08M$336.17M        
5/9/2024Q4 2024$0.88$0.90+$0.02$1.40$329.53M$343.00M      
2/8/2024Q4 2023$0.94$1.04+$0.10$1.47$320.84M$336.20M        
11/2/2023Q2 2024$0.94$0.99+$0.05$1.50$319.18M$318.18M  
8/8/2023Q2 2023$0.73$1.05+$0.32$1.30$292.74M$311.30M        
5/11/2023Q4 2023$0.68$0.77+$0.09$0.97$284.53M$304.42M  
2/7/2023Q3 2023$0.79$0.85+$0.06$1.06$300.47M$305.30M        

Haemonetics Earnings - Frequently Asked Questions

Haemonetics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based off last year's report dates. Learn more on HAE's earnings history.

Haemonetics issued an update on its FY 2025 earnings guidance on Thursday, November, 7th. The company provided EPS guidance of 4.450-4.750 for the period, compared to the consensus earnings per share estimate of 4.590. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

In the previous quarter, Haemonetics (NYSE:HAE) reported $1.12 earnings per share (EPS) to beat the analysts' consensus estimate of $1.09 by $0.03. Learn more on analysts' earnings estimate vs. HAE's actual earnings.

The conference call for Haemonetics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Haemonetics's latest earnings report can be read online.
Read Transcript

Haemonetics's earnings report can be found in their filing with the SEC.
View SEC filing

Haemonetics (NYSE:HAE) has a recorded annual revenue of $1.31 billion.

Haemonetics (NYSE:HAE) has a recorded net income of $117.56 million. HAE has generated $2.41 earnings per share over the last four quarters.

Haemonetics (NYSE:HAE) has a trailing price-to-earnings ratio of 37.02 and a forward price-to-earnings ratio of 19.44. The price/earnings-to-growth ratio is 1.39.

Haemonetics's earnings are expected to grow from $4.59 per share to $5.28 per share in the next year, which is a 15.03% increase.

`

More Earnings Resources from MarketBeat



This page (NYSE:HAE) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners